SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?

被引：3
|
作者：
Cervantes, Carlos Escobar [1 ]
机构：
[1] Univ Hosp La Paz, Cardiol Dept, Madrid 28046, Spain
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2024年 / 12卷 / 08期
关键词：
D O I：
10.1016/S2213-8587(24)00183-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [31] Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Winiarska, Agata
    Knysak, Monika
    Nabrdalik, Katarzyna
    Gumprecht, Janusz
    Stompor, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [32] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [33] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Pedro Cardoso
    Katie G. Young
    Anand T. N. Nair
    Rhian Hopkins
    Andrew P. McGovern
    Eram Haider
    Piyumanga Karunaratne
    Louise Donnelly
    Bilal A. Mateen
    Naveed Sattar
    Rury R. Holman
    Jack Bowden
    Andrew T. Hattersley
    Ewan R. Pearson
    Angus G. Jones
    Beverley M. Shields
    Trevelyan J. McKinley
    John M. Dennis
    Diabetologia, 2024, 67 : 822 - 836
  • [34] Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail N.
    DIABETES, 2021, 70
  • [35] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [36] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Cardoso, Pedro
    Young, Katie G.
    Nair, Anand T. N.
    Hopkins, Rhian
    Mcgovern, Andrew P.
    Haider, Eram
    Karunaratne, Piyumanga
    Donnelly, Louise
    Mateen, Bilal A.
    Sattar, Naveed
    Holman, Rury R.
    Bowden, Jack
    Hattersley, Andrew T.
    Pearson, Ewan R.
    Jones, Angus G.
    Shields, Beverley M.
    McKinley, Trevelyan J.
    Dennis, John M.
    DIABETOLOGIA, 2024, 67 (05) : 822 - 836
  • [37] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
  • [38] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [39] SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)
    Nguyen, Julia
    Nee, Robert
    Marneweck, Hava
    Banaag, Amanda
    Koehlmoos, Tracey
    Oliver, James
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [40] SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization
    Lyu, Beini
    Grams, Morgan
    Chang, Alex R.
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    DIABETES, 2021, 70
12345